These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1645332)
1. Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies. Hiraoka A; Masaoka T; Nagai K; Horiuchi A; Kanamaru A; Niimura M; Hamada T; Takahashi M J Antimicrob Chemother; 1991 Mar; 27(3):361-7. PubMed ID: 1645332 [TBL] [Abstract][Full Text] [Related]
2. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys. Soike K; Huang JL; Tu JI; Stouffer B; Mitroka JG; Swerdel M; Olsen S; Bonner DP; Tuomari AV; Field AK J Infect Dis; 1992 Apr; 165(4):732-6. PubMed ID: 1313071 [TBL] [Abstract][Full Text] [Related]
3. Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure. Machida H; Nishitani M; Ashida N Microbiol Immunol; 1994; 38(2):109-15. PubMed ID: 8041297 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice. Machida H; Ijichi K; Takezawa J Antiviral Res; 1992 Feb; 17(2):133-43. PubMed ID: 1554238 [TBL] [Abstract][Full Text] [Related]
5. Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients. Burdge DR; Voigt R; Lindley JI; Gage L; Sacks SL AIDS; 1995 Jul; 9(7):810-2. PubMed ID: 7546429 [No Abstract] [Full Text] [Related]
6. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus. Kawai H; Yoshida I; Suzutani T Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU. Machida H; Watanabe Y Microbiol Immunol; 1991; 35(2):139-45. PubMed ID: 1653394 [TBL] [Abstract][Full Text] [Related]
8. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1. Ijichi K; Ashida N; Varia S; Machida H Antiviral Res; 1993 May; 21(1):47-57. PubMed ID: 8391248 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386 [TBL] [Abstract][Full Text] [Related]
10. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines. Machida H; Ijichi K; Ohta A; Honda M; Niimura M Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. Bodsworth NJ; Boag F; Burdge D; Généreux M; Borleffs JC; Evans BA; Modai J; Colebunders R; Thomas M; DeHertogh D; Pacelli L; Thomis J J Infect Dis; 1997 Jul; 176(1):103-11. PubMed ID: 9207355 [TBL] [Abstract][Full Text] [Related]
12. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Sakuma T Antimicrob Agents Chemother; 1984 Jun; 25(6):742-6. PubMed ID: 6331298 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds. Machida H; Sakata S Antiviral Res; 1984 Jun; 4(3):135-41. PubMed ID: 6089657 [TBL] [Abstract][Full Text] [Related]
15. Retinal toxicity and ocular kinetics of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rabbits. Mochizuki K; Torisaki M; Yamashita Y; Komatsu M; Tanahashi T; Ijichi K; Machida H Graefes Arch Clin Exp Ophthalmol; 1994 Aug; 232(8):503-8. PubMed ID: 7926887 [TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication. Lin JC; Reefschläger J; Herrmann G; Pagano JS Antiviral Res; 1992 Jan; 17(1):43-52. PubMed ID: 1310582 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU. Ashida N; Sakata S; Kano F; Nishitani M; Watanabe Y; Machida H Antiviral Res; 1994 Dec; 25(3-4):179-84. PubMed ID: 7710267 [TBL] [Abstract][Full Text] [Related]